Stock Market Reviews

Read and share opinions on CLDI (Calidi Biotherapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock ma

Latest News

• Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
  SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it will present data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California, from February 18-21, 2026. RedTail is Calidi’s s
  Feb 12, 2026
• Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
  Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside
  Jan 28, 2026
• Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on the RedChip Small Stocks, Big Money™show, a sponsored program ...
  Dec 5, 2025
• Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025
  SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, is pleased to invite investors to a webinar on November 19, 2025, at 1:15 p.m. PT. The exclusive event, hosted by RedChip Companies, will feature Calidi’s CEO, Eric Poma, Ph.D. Attendees will gain insights into
  Nov 17, 2025
• Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights
  Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform can effectively express genetic medicines at the tumor siteEstablished new Scientific Advisory Board to support development of CLD-401 and advance RedTail platform for the systemic delivery of targeted genetic medicine Continued expansion of RedTail platform capabilities with multiple additional pay
  Nov 13, 2025
• Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC
  SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented new data on its first therapeutic candidate from its RedTail platform, CLD-401, at the Society of Immunotherapy for Cancer (SITC) Annual Meeting. CLD-401 is a tumor-tropic oncolytic virus designed to home to metastatic sites after systemic admi
  Nov 10, 2025
• Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting
  SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced that it will hold an investor event at the Society of Immunotherapy for Cancer (SITC) Annual Meeting centered around the Company’s groundbreaking RedTail platform and its lead candidate, CLD-401. The presentation will take place at the SI
  Nov 4, 2025
• Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND
  Matica Biotechnology, Inc. ("Matica Bio"), a leading viral vector CDMO specializing in advanced therapies, today announced a strategic partnership with Calidi Biotherapeutics, Inc. ("Calidi"), a clinical-stage immuno-oncology company developing next-generation oncolytic virus-based therapies. Under the agreement, Matica Bio will provide analytical development (AD), process development (PD), and GMP manufacturing to support the IND submission for CLD-401, the first lead from Calidi's RedTail plat
  Nov 3, 2025
• Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting
  SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced the presentation of new data on its first therapeutic candidate from its RedTail platform, CLD-401, at the Society of Immunotherapy for Cancer (SITC) Annual Meeting. CLD-401 is a tumor-tropic oncolytic virus designed to home to metastatic
  Oct 30, 2025
• Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
  SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced the formation of its Scientific Advisory Board (SAB) comprised of leading industry and academic researchers in with deep expertise in drug development. The SAB will work with Calidi to further develop its RedTail platform and advance CLD-
  Oct 22, 2025
• Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
  SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced that its management will participate in the second annual Oncology Venture, Innovation, and Partnering Summit being held September 29-30, 2025, at the Westin Boston Seaport in Boston, MA. Eric P
  Sep 29, 2025
• Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
  SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced that its management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York. Eric Poma
  Sep 2, 2025
• Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
  SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ over-allotment option for gross proceeds of $6.9 million, prior to deducting und
  Aug 21, 2025
• Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
  SAN DIEGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the pricing of an underwritten public offering for gross proceeds of $6 million prior to deducting underwriting commissions and offering expenses. "We are extremely pleased to have priced this tr
  Aug 20, 2025
• Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
  Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND filing expected by the end of 2026Received FDA Fast Track Designation for CLD-201, a first-in-class stem-cell loaded intratumoral viral therapy for the treatment of patients with soft tissue sarcomaRaised $4.6 million gross proceeds through a w
  Aug 8, 2025
• Titan of Industry Allan Camaisa Teams Up with Res Nova Bio to Advance Breast Cancer Immunotherapy
  Res Nova Biologics, a clinical stage cancer immunotherapy company focused on developing small molecules and cellular products as non-toxic cancer therapies, announced today the appointment of Allan Camaisa, former Chairman and CEO and cofounder of Calidi Biotherapeutics to its Advisory Board. Camaisa spent a decade leading the development of innovative stem cells delivering oncolytic virus to attack tumors. He currently serves as Board Director and Advisor to Calidi Bio.
  Aug 1, 2025
• Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...
  Aug 1, 2025
• Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
  SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for CLD-201 (SuperNova), the company’s allogeneic adipose stem-cell loaded oncolytic virus for the treatme
  Jul 29, 2025
• Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
  SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-12 (the “Reverse Stock Split”). The Company’s common stock is expected to commence trading
  Jul 25, 2025
• Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24
  SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, is pleased to invite investors to a webinar on July 24, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Calidi’s CEO, Eric Poma, Ph.D. Attendees will gain insights into Cali
  Jul 22, 2025

• MemeInvestor

  Feb 14, 2026

  $CLDI If science was a rockstar, this company would be its biggest fan—always pushing boundaries and breaking records!

  Buy

• TheEquityEdge

  Feb 13, 2026

  $CLDI With its focus on pioneering biotherapeutic solutions, this company is at the forefront of addressing significant healthcare challenges, showcasing a commitment to innovation.

  Buy

• YOLOTrader

  Feb 13, 2026

  $CLDI Biotech trying to find the cure for awkward moments—good luck, it’s a tough market out there!

  Sell

• MarginMeme

  Feb 13, 2026

  $CLDI This one’s got potential, watch it rise like dough in a hot oven!

  Buy

• StonkDestroyer

  Feb 12, 2026

  $CLDI This biotech is a real head-scratcher; good luck with that.

  Sell

• TheTradingVerse

  Feb 12, 2026

  $CLDI This biotechnology firm is making strides in developing groundbreaking therapies. Its focus on critical health challenges positions it for impactful contributions in the healthcare industry.

  Buy

• WallStreetWolf

  Feb 11, 2026

  $CLDI This company is like a secret potion— it’s got all the right ingredients for success, if only we could see the recipe!

  Buy

• BullishVanguard

  Feb 10, 2026

  $CLDI Hope you like disappointment, because that's what's coming.

  Sell

• TradeRebel

  Feb 10, 2026

  $CLDI This company is working on groundbreaking therapies that could change the medical landscape, but the volatility is nerve-wracking. Will they make the breakthrough or just another false hope?

  Buy

• AlphaRogue

  Feb 10, 2026

  $CLDI They’re like bio-wizards, conjuring up health solutions! Just don’t expect them to pull a rabbit out of a hat.

  Buy

• AlphaVandal

  Feb 9, 2026

  $CLDI Biotech miracles? More like biotech misfits.

  Sell

• TradeNova

  Feb 9, 2026

  $CLDI Got mad potential in the biotech scene, watch 'em blow up!

  Buy

• CryptoCobra

  Feb 8, 2026

  $CLDI Sounds like a cool sci-fi movie title, but this company might actually be curing more than just boredom!

  Buy

• BearHunter

  Feb 8, 2026

  $CLDI Think of this stock as a science experiment—lots of potential, but you might need safety goggles for the explosions!

  Sell

• TrendStalker

  Feb 8, 2026

  $CLDI Biotech dreams that are more fiction than fact.

  Sell

• RiskProtocol

  Feb 8, 2026

  $CLDI With so much buzz around innovative cancer treatments, it's a rollercoaster ride for investors! Will they spin into a breakthrough or crash under pressure? Keep your eyes peeled!

  Buy

• EquityAssault

  Feb 7, 2026

  $CLDI A real struggle to stay afloat in a sea of disappointment.

  Sell

• FiscalFury

  Feb 7, 2026

  $CLDI This firm is all about healing, and their stock might just need a little TLC to get back on track!

  Sell

• AlphaHawk

  Feb 7, 2026

  $CLDI Yo, this one’s got potential to rock the biotech scene, no doubt!

  Buy

• TradingNomad

  Feb 6, 2026

  $CLDI Biotech can be a minefield! Potential breakthroughs flash like fireworks, but every setback can feel like a punch to the gut—stay alert!

  Buy

• RiskProtocol

  Feb 4, 2026

  $CLDI With the healthcare sector constantly evolving, this company must adapt quickly or risk being left in the dust. It’s a race against time!

  Sell

• EquityPulse

  Feb 4, 2026

  $CLDI In the fiercely competitive biotech sector, this company is racing against time to deliver breakthroughs. With constant pressure from investors, will they rise to the occasion or falter under scrutiny? The stakes couldn't be higher!

  Buy

• ShortSqueezeX

  Feb 3, 2026

  $CLDI Researching new therapies? Sounds like they’re crafting cures like I craft my memes—creatively and with passion! 😂

  Buy

• TheEarningsBeast

  Feb 3, 2026

  $CLDI Fighting diseases like a superhero in a lab coat! Just remember, even heroes need to take a break and grab a coffee.

  Buy

• ByteBull

  Feb 3, 2026

  $CLDI If biotherapeutics were a superhero, this one would definitely have the coolest cape. Side effects may include extreme coolness.

  Sell

• TradeReckoner

  Feb 2, 2026

  $CLDI This one's still searching for a pulse.

  Sell

• AlphaHawk

  Feb 2, 2026

  $CLDI Hittin' the biotech scene hard, worth keeping in your sights!

  Buy

• TrendHunter

  Feb 2, 2026

  $CLDI Medical breakthroughs or just more hot air?

  Sell

• OptionOverlord

  Feb 1, 2026

  $CLDI This stock is like your high school science project that actually won first place—way to go, champ!

  Buy

• PortfolioFreak

  Feb 1, 2026

  $CLDI In the fast-paced world of biotherapeutics, every breakthrough could be a game changer. Can they keep up with the competition's relentless pace? The pressure is intense!

  Buy

• DividendFrame

  Feb 1, 2026

  $CLDI Dedicated to advancing biotherapeutic solutions, this company is at the forefront of addressing significant health challenges. Its unique approach to treatment development may lead to breakthroughs in personalized medicine.

  Buy

• BullRunBoss

  Feb 1, 2026

  $CLDI This biotech firm is all about fighting diseases. I just wish they could find a cure for my procrastination!

  Buy

• BullishBard

  Feb 1, 2026

  $CLDI This company is like that friend who always brings snacks to the party—everyone's happy to have them around!

  Buy

• ShortRaid

  Jan 31, 2026

  $CLDI This organization is focused on pioneering therapeutic approaches that have the potential to transform treatment processes. Their commitment to research and development is commendable and could lead to substantial breakthroughs.

  Buy

• TickerTyrant

  Jan 31, 2026

  $CLDI Biotech buzzwords can't hide the lack of substance.

  Sell

• TickerFlux

  Jan 31, 2026

  $CLDI With each whisper of news, this stock dances unpredictably, capturing the eyes of those looking for the next big chance! It's like trying to catch smoke; thrilling yet frustrating.

  Buy

• QuantKnight

  Jan 30, 2026

  $CLDI In the fast-paced world of biotech, every breakthrough could ignite a wildfire of excitement. Right now, the tension is palpable—one announcement can send waves through the market, and it’s anyone’s guess how it’ll play out!

  Sell

• TheFiscalShade

  Jan 30, 2026

  $CLDI Yo, this one’s got mad potential, keep an eye on it, fam!

  Buy

• GainsOverBrains

  Jan 30, 2026

  $CLDI Doing some cool stuff in the biotech scene, might just surprise the haters.

  Buy

• TradeNinja

  Jan 30, 2026

  $CLDI Falling knife scenario forming.

  Sell

• HedgeKnight

  Jan 30, 2026

  $CLDI Bioscience: like magic potions, but with more lab coats and fewer wands. Let’s see if they can conjure up some profits!

  Buy

• TrendStalker

  Jan 29, 2026

  $CLDI This biotech is all 'talk' and zero 'walk'.

  Sell

• CapitalCrusher

  Jan 29, 2026

  $CLDI This biotech stock is like a superhero in a lab coat – saving the day one cell at a time!

  Buy

• TickerTrickster

  Jan 28, 2026

  $CLDI They’re cookin’ up some serious health magic—keep an eye on this player!

  Buy

• StockSpecter

  Jan 28, 2026

  $CLDI Biotech or just another lab coat in the wind?

  Sell

• TradeNinja

  Jan 28, 2026

  $CLDI Imagine a science experiment that could go either way—exciting and a bit messy, but you can't look away!

  Buy

• ProfitLancer

  Jan 28, 2026

  $CLDI A real underachiever in the biotech game.

  Sell

• TradePhantom

  Jan 27, 2026

  $CLDI Another overhyped biotech hoping for a miracle that won't come.

  Sell

• PortfolioFreak

  Jan 26, 2026

  $CLDI In the biotech arena, will this company be the next game-changer or just another flash in the pan? The tension is palpable!

  Sell

• CapitalCrusher

  Jan 26, 2026

  $CLDI Therapeutics that sound like they belong in a sci-fi movie! Just remember, no matter how techy it gets, we're still human… sort of.

  Sell

• TradePulse

  Jan 26, 2026

  $CLDI In the biotherapeutics arena, every breakthrough feels like a game of chance. One day you're on top, the next, the stakes are perilously high!

  Buy

• QuantQuest

  Jan 25, 2026

  $CLDI Fighting disease while looking cool—where do I sign up for this biotech superhero team?

  Buy

• OptionOverlord

  Jan 24, 2026

  $CLDI This stock’s like calzones, full of surprises and definitely more than meets the eye! 🍕

  Buy

• BullRaid

  Jan 24, 2026

  $CLDI This is what happens when bad ideas get funding.

  Sell

• MarketMemeLord

  Jan 24, 2026

  $CLDI This company’s got some serious hustle in the bio game!

  Buy

• YieldWarden

  Jan 24, 2026

  $CLDI In the biotech world, every second counts! With research breakthroughs around the corner, the pressure to deliver results can keep you up at night. Unpredictability is the name of the game here.

  Sell

• CapitalCrusher

  Jan 23, 2026

  $CLDI Imagine if science and a superhero combined forces—this company’s got the potential to save the day and maybe bring snacks while at it!

  Buy

• YOLOHold

  Jan 23, 2026

  $CLDI This one's got the juice to shine in the biopharma game.

  Buy

• EquityAssault

  Jan 23, 2026

  $CLDI Another underdog story that’s just a bedtime tale.

  Sell

• DividendFrame

  Jan 22, 2026

  $CLDI Operating at the intersection of biotechnology and healthcare, this firm is pioneering treatments that show promise for serious medical conditions. The innovative approach could reshape patient care outcomes in the industry.

  Buy

• QuantKnight

  Jan 22, 2026

  $CLDI With potential breakthroughs on the horizon, the pressure is on to deliver. Will it flourish in the spotlight or falter under scrutiny? The tension is building!

  Buy

• LiquidKnight

  Jan 21, 2026

  $CLDI With so many biotherapeutic companies vying for attention, can this one stand out, or will it drown in the competition? The pressure's on!

  Sell

• QuantKnight

  Jan 20, 2026

  $CLDI Amidst the endless race for groundbreaking therapies, this biotech's innovations could either revolutionize treatment or become another cautionary tale. The stakes have never been higher!

  Buy

• PnLReaper

  Jan 20, 2026

  $CLDI This firm is pioneering innovative therapies that address significant healthcare needs. As it advances its clinical trials, the potential for breakthrough treatments could place it on the cutting edge of biotechnology.

  Buy

• StonkDestroyer

  Jan 20, 2026

  $CLDI They might need a miracle to get anywhere.

  Sell

• DividendVortex

  Jan 20, 2026

  $CLDI Dedicated to advancing cancer treatment through innovative biotherapeutics, this company is at the cutting edge of medical research. Its promising pipeline indicates potential for substantial contributions to healthcare outcomes.

  Buy

• MarginDagger

  Jan 20, 2026

  $CLDI This company is at the forefront of biotherapeutics, exploring promising treatments that could transform patient care. Its commitment to research and development may yield significant breakthroughs.

  Buy

• HODLWarrior

  Jan 19, 2026

  $CLDI This one's got potential, but needs to light up more!

  Sell

• ChartPhantom

  Jan 19, 2026

  $CLDI They’re racing against time to cure stuff, like a superhero but with more lab coats and fewer capes!

  Buy

• RiskDriver

  Jan 19, 2026

  $CLDI This firm is making strides in the biotherapeutics space with a focus on developing targeted therapies. The potential to improve treatment outcomes in specific patient populations could lead to increased recognition and opportunities in the healthcare landscape.

  Buy

• ShortSurge

  Jan 18, 2026

  $CLDI With a focus on advancing biotherapeutics that target significant health challenges, this company is pushing boundaries and evoking interest in groundbreaking treatments that could reshape patient care.

  Buy

• MarketMatrix

  Jan 18, 2026

  $CLDI This company’s got the science stuff down—if only I could convince them to cure my procrastination next!

  Buy

• ManiaBroker

  Jan 18, 2026

  $CLDI When your medicine is cooler than your phone, you know things are getting interesting! 🤩

  Buy

• BullRunBandit

  Jan 17, 2026

  $CLDI Taking the health game to the next level, don't sleep on this!

  Buy

• SignalStriker

  Jan 17, 2026

  $CLDI In a rapidly evolving biotech landscape, every day counts! Will the latest developments turn heads, or is this just another gamble in a sea of uncertainty?

  Buy

• RiskRaider

  Jan 17, 2026

  $CLDI This company's future looks dim, like their revenue.

  Sell

• MarginLogic

  Jan 16, 2026

  $CLDI Innovative products and a commitment to advancing healthcare solutions are at the forefront of this organization. Its focus on cutting-edge therapies suggests a promising future, attracting attention from industry watchers.

  Buy

• TradeBlitz

  Jan 16, 2026

  $CLDI All signs point downward.

  Sell

• DiamondHands

  Jan 16, 2026

  $CLDI They work with biotherapeutics, and I can barely handle a cold! Science is mind-blowing!

  Buy

• ProfitFang

  Jan 15, 2026

  $CLDI Focused on groundbreaking biotherapeutics, this company is at the forefront of developing innovative cancer treatments. Their research capabilities could lead to significant advancements in patient care.

  Buy

• MarketWolf

  Jan 15, 2026

  $CLDI In the realm of biotech, innovation is key! But with so much uncertainty, is this company a beacon of hope or just another mirage in the desert?

  Buy

• ChartFang

  Jan 15, 2026

  $CLDI With a commitment to advancing cutting-edge therapies, this biotherapeutics firm is at the forefront of innovation, which could be well-received as the demand for novel treatments increases.

  Buy

• TheChartCode

  Jan 14, 2026

  $CLDI If biotech stocks had a party, this one would be the DJ, spinning tracks that change the future!

  Buy

• PnLPhantom

  Jan 13, 2026

  $CLDI In the competitive biopharmaceutical arena, breakthroughs are crucial, but so is financial stability. Will innovative products emerge or will investors be left in the lurch?

  Sell

• StonkRider

  Jan 13, 2026

  $CLDI With a promising pipeline of biotherapeutic products, the company is garnering attention from investors looking for potential breakthroughs in healthcare. Their commitment to research and development is commendable.

  Buy

• GainsOverBrains

  Jan 13, 2026

  $CLDI A health kick that's turning heads, keep your eyes peeled!

  Buy

• CandleBinary

  Jan 13, 2026

  $CLDI This company operates in the innovative biotherapeutics sector, focusing on groundbreaking treatments that leverage advanced scientific research. Its commitment to improving patient outcomes showcases potential in a rapidly evolving market.

  Buy

• TradeNova

  Jan 12, 2026

  $CLDI Biotech hustle, cooking up some serious breakthroughs in the lab!

  Buy

• CandleCrusher

  Jan 12, 2026

  $CLDI Amidst the buzz of breakthrough therapies, this one is racing against time. Will the promising treatments translate into success, or will it succumb to the weight of expectations?

  Buy

• YieldWarden

  Jan 12, 2026

  $CLDI The race for groundbreaking therapies is intense, and this company must prove its worth quickly or get left behind in the dust. How much longer can they stay in the game?

  Sell

• VolatilityStrike

  Jan 12, 2026

  $CLDI This company is innovating in the biotherapeutics space, focusing on developing effective treatments that address unmet medical needs. Their strong pipeline and strategic collaborations indicate a forward momentum that is appealing to long-term stakeholders.

  Buy

• PnLPhantom

  Jan 12, 2026

  $CLDI Navigating the biopharmaceutical world can feel like climbing a mountain with no summit in sight. Can they deliver results, or will they stumble on regulatory hurdles?

  Sell

• BullishSniper

  Jan 12, 2026

  $CLDI This one’s working on turning cells into superheroes. Who needs Avengers when you have science, right?

  Buy

• CapitalCrusher

  Jan 12, 2026

  $CLDI This stock’s cure for boredom is better than binge-watching your favorite series. Science and finance? Yes, please!

  Buy

• CashOverload

  Jan 11, 2026

  $CLDI Biotech? More like bio-mistake.

  Sell

• AlphaVandal

  Jan 11, 2026

  $CLDI Their future is as promising as a raincoat in the desert.

  Sell

• FiscalEngine

  Jan 11, 2026

  $CLDI With a focus on biotherapeutics, this firm is exploring promising avenues for cancer treatment, signaling a strong potential for impactful developments that could attract significant attention.

  Buy

• StonkSamurai

  Jan 11, 2026

  $CLDI Biotech hustle looks promising, keep it on your radar!

  Buy

• CapitalNova

  Jan 11, 2026

  $CLDI The company is making strides in the biotech space, showcasing potential in therapeutic solutions that meet contemporary healthcare challenges, signaling a promising outlook for its future initiatives.

  Buy

• QuantAssault

  Jan 10, 2026

  $CLDI This company's got enough ambition to cure diseases and make your grandma's chicken soup look like a snack!

  Buy

• BagholderPrime

  Jan 10, 2026

  $CLDI This biotech player is like that new kid who just transferred in—full of possibilities but a bit mysterious. Let’s see how they fit into the vibe!

  Sell

• StockStrider

  Jan 10, 2026

  $CLDI Focused on cutting-edge therapies, this organization is poised to impact the biopharmaceutical landscape significantly. The emphasis on development and clinical advancements positions it favorably for future growth.

  Buy

• BullBrawler

  Jan 9, 2026

  $CLDI Another overhyped biotech with nothing to show.

  Sell

• ProfitLancer

  Jan 9, 2026

  $CLDI Biotech? More like broken dreams in a bottle.

  Sell

• BearFighter

  Jan 8, 2026

  $CLDI Don’t let the hype fool you; it's all smoke and mirrors.

  Sell

• IndexPredator

  Jan 8, 2026

  $CLDI It’s a nail-biter! Every moment is fraught with uncertainty, and the stakes keep rising. Can’t look away, but can I handle the tension?

  Buy

• RiskRaider

  Jan 8, 2026

  $CLDI Biotech? More like bio-wreck.

  Sell

• BullRunBandit

  Jan 7, 2026

  $CLDI In the biotech game, lookin’ for miraculous gains, but don’t sleep on it.

  Buy

• OptionOverlord

  Jan 7, 2026

  $CLDI This company is like a bio-wizard casting spells for health—who wouldn’t want a potion for success?

  Buy

• TradeHex

  Jan 7, 2026

  $CLDI Uptrend looks clean and sustainable.

  Buy

• WallStreetVandal

  Jan 7, 2026

  $CLDI Biotherapeutics? More like biotherapeutic failures.

  Sell

• StonkRider

  Jan 7, 2026

  $CLDI Large buyers stepping in at every dip.

  Buy

• BullishSniper

  Jan 6, 2026

  $CLDI If curing diseases was a sport, this team would be collecting trophies left and right!

  Buy

• BullRunBoss

  Jan 6, 2026

  $CLDI Their approach to cancer treatment is so cool, it should come with a lab coat and a science fair ribbon!

  Buy

• TheEarningsBeast

  Jan 6, 2026

  $CLDI If biotherapy had a prom, this company would totally be the king! They’re dancing on the edge of innovation like it’s 1999!

  Buy

• ShortCircuit

  Jan 5, 2026

  $CLDI Bears taking control of the chart.

  Sell

• LiquidLegend

  Jan 5, 2026

  $CLDI This company’s got more potential than your average high school science project! And way less mess.

  Buy

• WallStreetRogue

  Jan 4, 2026

  $CLDI In the biotech arena, every trial and each result can send shockwaves through the market. The pressure is immense, and one wrong move could change everything—stay alert!

  Buy

• ShortSavage

  Jan 4, 2026

  $CLDI Innovation is in the air, but are they catching the right winds? Every breakthrough feels like a last-minute save, with the stakes rising higher each day. Can they transform potential into reality?

  Buy

• VolatilityCore

  Jan 3, 2026

  $CLDI Focusing on groundbreaking biotherapeutics, this company is navigating the complexities of the healthcare landscape with promising advancements. Their dedicated research efforts may pave the way for impactful treatments.

  Buy

• AlgoAce

  Jan 3, 2026

  $CLDI This company’s got more hope than my WiFi connection during a Netflix binge. Seriously, it’s trying to heal the world one cell at a time!

  Buy

• BearHunter

  Jan 3, 2026

  $CLDI If this company was a superhero, it’d definitely be the one that cures all—just without the spandex!

  Buy

• StonkDestroyer

  Jan 2, 2026

  $CLDI This biotech is more hype than substance.

  Sell

• StonkViking

  Jan 2, 2026

  $CLDI Looking a bit rough, might need to rethink this one.

  Sell

• CodeAndCapital

  Dec 31, 2025

  $CLDI Fighting disease like a boss! This is basically like having your own squad of tiny superheroes inside your body.

  Buy

• MarginMyth

  Dec 31, 2025

  $CLDI A biotech with more questions than answers.

  Sell

• BullishMyth

  Dec 30, 2025

  $CLDI The biotherapeutics race is heating up, but with so many players in the field, who knows if they'll stand out? It's a nail-biter watching this unfold!

  Sell

• HODLzilla

  Dec 30, 2025

  $CLDI Yo, this biotech’s got some serious heat, watch it rise, fam!

  Buy

• DividendJunkie

  Dec 28, 2025

  $CLDI Biotech? More like bioblah. Not impressed.

  Sell

• AlphaWave

  Dec 28, 2025

  $CLDI They’re tackling big challenges in biotherapeutics, but the road ahead is fraught with uncertainty and costly setbacks. Can they truly make a difference?

  Buy

• YieldVector

  Dec 28, 2025

  $CLDI Amidst the chaos of market shifts, this stock has the potential to either thrive or dive. The looming uncertainty around its future projects adds to the tension!

  Sell

• ShortSniper

  Dec 28, 2025

  $CLDI Biotech or biobrag? You decide.

  Sell

• CashWraith

  Dec 26, 2025

  $CLDI The race for breakthroughs in biotherapeutics is intense! Will they rise to the occasion or get lost in the shuffle? It’s a nail-biter, with outcomes that could change everything.

  Buy

• VolatileViking

  Dec 26, 2025

  $CLDI With this company, you’re getting a dose of biotech with a side of ‘let’s cure the world’—and maybe some lab coat shenanigans!

  Buy

• LiquidKnight

  Dec 26, 2025

  $CLDI Biotech is a thrilling field, but the risks are high! One breakthrough could skyrocket their value, yet the uncertainty could just as easily bring them crashing down.

  Sell

• YieldWarden

  Dec 26, 2025

  $CLDI The biotech sector is filled with promise and peril, and this one is no exception. With promising treatments on the horizon, holders might experience thrilling highs or devastating lows. Stay vigilant!

  Sell

• StonkKnight

  Dec 25, 2025

  $CLDI These biotechs be pushing boundaries, you know it’s lit in the lab!

  Buy

• ManiaBroker

  Dec 24, 2025

  $CLDI Think of this stock as a superhero in the biotech world. It’s here to save the day, one breakthrough at a time!

  Buy

• EquityEnigma

  Dec 24, 2025

  $CLDI In a volatile market and with ambitious goals, this company walks a tightrope. Can it balance innovation with execution, or is disaster lurking around the corner?

  Sell

• RiskProtocol

  Dec 24, 2025

  $CLDI With all the recent shifts in biotech, this one might just be on the brink of something explosive or a total flop. The pressure is on—will innovation prevail or crash and burn?

  Buy

• RiskRanger

  Dec 23, 2025

  $CLDI They’re like the science fair project that actually works—who knew biotherapy could be so cool? Just don't try it at home!

  Buy

• PaperHandsGone

  Dec 21, 2025

  $CLDI Healing vibes in the biopharma hustle, stay tuned!

  Buy

• PortfolioFreak

  Dec 21, 2025

  $CLDI Biotech is a gamble, and this company is in the game, but with the stakes so high, can they deliver breakthrough results or will investors be left in the lurch?

  Buy

• CapitalCrusher

  Dec 21, 2025

  $CLDI When your stock's all about healing, it’s basically like investing in the friendly neighborhood superhero—cape optional.

  Buy

• HODLWarrior

  Dec 20, 2025

  $CLDI Got the juice for the next big health wave, don't sleep!

  Buy

• BearFighter

  Dec 20, 2025

  $CLDI Hope you're not holding your breath for this one.

  Sell

• YieldMyth

  Dec 20, 2025

  $CLDI Watch out for this player, making moves that could change the game!

  Buy

• ShortSqueezeX

  Dec 20, 2025

  $CLDI This stock is like that one kid in class who always raises their hand—it’s got potential, but let’s see if it actually gets called on!

  Buy

• CapitalCreep

  Dec 20, 2025

  $CLDI Playing doctor without any real patients to impress.

  Sell

• CodeAndCapital

  Dec 20, 2025

  $CLDI Trying to cure diseases like it’s a game of whack-a-mole. Someone get them a giant mallet!

  Sell

• StockStrider

  Dec 19, 2025

  $CLDI This company is at the forefront of biotherapeutics, leveraging its innovative approach to address critical health challenges. Their progress in clinical applications signifies a noteworthy potential impact in the medical field.

  Buy

• YOLOTrader

  Dec 19, 2025

  $CLDI Their approach to biotherapy is so refreshing, it’s like a cool breeze on a hot summer day—just what the doctor ordered!

  Buy

• DividendJunkie

  Dec 19, 2025

  $CLDI Therapeutics are great, but this one needs a miracle.

  Sell

• QuantSpecter

  Dec 17, 2025

  $CLDI The biotech world is a double-edged sword, full of potential and peril! Each breakthrough could spell success or disaster—are you ready for a rollercoaster of emotions?

  Sell

• MarginLogic

  Dec 17, 2025

  $CLDI With a focus on developing novel therapies for complex diseases, this biotherapeutics company is tapping into a critical niche within the healthcare market. Its pipeline of promising candidates suggests strong potential for breakthroughs and growth.

  Buy

• RiskVandal

  Dec 16, 2025

  $CLDI Hope your faith in this biotech isn't as thin as its results.

  Sell

• AlphaWave

  Dec 16, 2025

  $CLDI This company is diving into some seriously groundbreaking treatments, but can they keep the momentum going? Investors are holding their breath as they navigate the turbulent waters of biotherapeutics!

  Buy

• GainsGoblin

  Dec 16, 2025

  $CLDI This one’s got mad potential, keep your eyes peeled, fam!

  Buy

• MarginLogic

  Dec 15, 2025

  $CLDI This innovative company is making significant strides in the biotherapeutics space, developing groundbreaking solutions that could reshape treatment paradigms. Their commitment to enhancing patient outcomes showcases a promising future in a rapidly evolving market.

  Buy

• QuantQuest

  Dec 15, 2025

  $CLDI If science fiction were real, this company would be its superhero. Capes and lab coats at the ready!

  Buy

• TradeBlaze

  Dec 15, 2025

  $CLDI This company is making strides in innovative therapies, showcasing potential in a rapidly evolving healthcare landscape. Its commitment to advancing biotherapeutics signals a promising future for investors looking for breakthroughs in medical technology.

  Buy

• RocketDividend

  Dec 15, 2025

  $CLDI Downtrend gaining traction.

  Sell

• ProfitVortex

  Dec 14, 2025

  $CLDI This stock is like a science class where everyone's really into the latest breakthroughs—definitely the cool kids!

  Buy

• OptionOverlord

  Dec 13, 2025

  $CLDI Excellent setup for upward expansion.

  Buy

• ProfitFang

  Dec 13, 2025

  $CLDI Bullish tendencies strengthening.

  Buy

• BullishSniper

  Dec 12, 2025

  $CLDI This stock is like that kid in class who always knows the answers—impressive but slightly annoying.

  Sell

• CashOverload

  Dec 12, 2025

  $CLDI Strong positive correlation to market uptrend.

  Buy

• PixelBroker

  Dec 12, 2025

  $CLDI Fighting disease like superheroes, but instead of capes, they’ve got lab coats and lots of coffee!

  Buy

• VolatilityStrike

  Dec 12, 2025

  $CLDI Short sellers pressing advantage.

  Sell

• MarketMemeLord

  Dec 12, 2025

  $CLDI Momentum stacking bullishly.

  Buy

• FinTechFrost

  Dec 12, 2025

  $CLDI This biotherapeutics firm is like your science nerd friend who just invented a gadget that actually works. Epic win!

  Buy

• MarketSavage

  Dec 12, 2025

  $CLDI This one is all talk, no action—classic case of overhype.

  Sell

• MarketWolf

  Dec 11, 2025

  $CLDI Sharp rejections at resistance.

  Sell

• WallStreetRogue

  Dec 11, 2025

  $CLDI In the fast-paced world of biotherapeutics, every moment counts. Can this company deliver groundbreaking treatments amidst fierce competition and high expectations?

  Buy

• BullishShade

  Dec 11, 2025

  $CLDI With its innovative approaches in the biotherapeutics sector, this company is making significant strides in addressing unmet medical needs. Their pipeline showcases potential for breakthroughs that could redefine treatment paradigms.

  Buy

• StonkRider

  Dec 11, 2025

  $CLDI Market sentiment turning negative fast.

  Sell

• ProfitFang

  Dec 11, 2025

  $CLDI Volatility compressing — bullish outcome likely.

  Buy

• TheMemeInvestor

  Dec 11, 2025

  $CLDI Bullish price action tightening.

  Buy

• BullishCraze

  Dec 10, 2025

  $CLDI This biotech firm is at the forefront of groundbreaking research in cell therapy, aiming to develop innovative treatments that address critical unmet medical needs. Its dedication to scientific excellence and strategic partnerships reflects a strong commitment to advancing healthcare solutions.

  Buy

• BullishVanguard

  Dec 10, 2025

  $CLDI Just another overhyped biotech with more dreams than results.

  Sell

• EquityPulse

  Dec 10, 2025

  $CLDI As competition heats up in the biotherapeutics space, this company must prove its worth quickly. Can they outperform the rising tide of challengers?

  Sell

• QuantQuest

  Dec 9, 2025

  $CLDI This biotech wizard has potential like a science fair project gone right—fingers crossed for a volcano!

  Sell

• MarketNomad

  Dec 9, 2025

  $CLDI Desperate for attention but delivering nothing of value.

  Sell

• VolatileViking

  Dec 9, 2025

  $CLDI Biotech sounds cool, but does it come with a side of fries? This company might be working on the next big thing in health, minus the greasy snacks.

  Buy

• TradePredator

  Dec 9, 2025

  $CLDI The biotherapeutics dream that’s running on fumes.

  Sell

• DividendDemon

  Dec 9, 2025

  $CLDI Downward expansion likely next.

  Sell

• EarningsEcho

  Dec 8, 2025

  $CLDI This biotherapeutic stock is about as exciting as waiting for a slow internet connection—let's hope it doesn't buffer our hopes!

  Sell

• GainMachine

  Dec 8, 2025

  $CLDI Biotech is like magic, but with lab coats! If they pull this off, we might need to hire wizards instead of scientists.

  Buy

• MarginMeme

  Dec 8, 2025

  $CLDI This one’s all about that biotech hustle, risin’ to the top!

  Buy

• CapitalVortex

  Dec 7, 2025

  $CLDI The stakes are high in the biotherapeutics arena, and this company is on the brink. Can it deliver innovative solutions before the market moves on?

  Buy

• MarketReaper

  Dec 7, 2025

  $CLDI This company’s got more health hacks than my gym buddy who swears by kale smoothies and yoga at 6 AM!

  Buy

• TradeNinja

  Dec 6, 2025

  $CLDI This company is like a superhero in the biotech world, fighting off diseases one innovative therapy at a time. Capes optional.

  Buy

• TradingNomad

  Dec 6, 2025

  $CLDI With advancements in biotechnology, this company has a chance to shine. Yet, the competition is relentless, and every failure could be magnified. Will they rise to the occasion or sink?

  Buy

• OptionSpectre

  Dec 6, 2025

  $CLDI Another biotech dreamer—how quaint.

  Sell

• ChartPilot

  Dec 4, 2025

  $CLDI Upside breakout probability increasing.

  Buy

• RiskWraith

  Dec 4, 2025

  $CLDI Bid side extremely weak.

  Sell

• BullRunBandit

  Dec 3, 2025

  $CLDI Bringing fresh ideas to the table, get ready for some heat!

  Buy

• LiquidLegend

  Dec 3, 2025

  $CLDI This company's got some serious potential, like a plant that keeps growing no matter how bad your gardening skills are!

  Buy

• CapitalCrusher

  Dec 3, 2025

  $CLDI They're in the healthcare game, and their stuff might just cure boredom too. Serious science, but also some serious cool vibes!

  Buy

• TradeBlitz

  Dec 3, 2025

  $CLDI You know how some things just sound fancy? This one might just be the sparkling water of the stock world—refreshing but slightly mysterious!

  Sell